Study,Year,Data source,ID: CRS,ID: CTG,Char: Methods,Char: Participants,Char: Interventions,Char: Outcomes,Char: Notes
Banaszewska 2011,2009,PUB,2836458,NCT00396513,"<p><b>Sequence generation and allocation:</b> participants allocated to 3 groups in 1:1:1 allocation ratio with block sizes of 6, 9, and 12. Random number table and block size determination.</p><p><b>Blinding:</b> open-label</p><p><b>Study period:</b> December 2006–March 2009</p>","<p><b>Inclusion criteria</b></p><ul><li>PCOS diagnosis based on the modified Rotterdam criteria: ≥ 2 of:</li><ul><li>clinical or chemical hyperandrogenism;</li><li>oligomenorrhoea or amenorrhoea; or</li><li>polycystic ovaries as viewed by transvaginal ultrasound.</li></ul><li>Normal baseline renal function tests, bilirubin, and aminotransferases</li></ul><p><b>Exclusion criteria</b></p><ul><li>Congenital adrenal hyperplasia</li><li>Cushing syndrome</li><li>Androgen-secreting tumours</li><li>Thyroid disease</li><li>Hyperprolactinaemia</li><li>Diabetes mellitus</li><li>Use of any OCP, steroids, or medications that interfere with steroid hormones, ovarian functions, insulin sensitivity, or lipid metabolism within 3 months of starting trial</li></ul><p><b>Compliance to statins:</b> not reported</p>",<p><b>Intervention(s)</b></p><ul><li>Simvastatin 20 mg orally once a day plus metformin 850 mg orally twice a day</li><li>Simvastatin 20 mg orally once a day</li></ul><p><b>Comparator(s)</b></p><ul><li>Metformin 850 mg orally twice a day</li></ul><p><b>Treatment duration:</b> 6 months (with intermediate analysis at 3 months)</p><p><b>Comedication: </b>none</p>,<p><b>Primary outcome(s)</b></p><ul><li>Testosterone level (total and free) by electro-chemiluminescence assay</li></ul><p><b>Secondary outcome(s)</b></p><ul><li>Number of spontaneous menses per 6 months</li><li>Ovarian volume</li><li>BMI*</li><li>Hirsutism measured on the Ferriman-Gallwey scale*</li><li>Acne measured with acne scale*</li><li>Serum LH</li><li>Serum FSH</li><li>Serum prolactin*</li><li>SHBG*</li><li>LDL cholesterol</li><li>HDL cholesterol</li><li>Total cholesterol</li><li>Triglycerides</li><li>sVCAM-1</li><li>Serum DHEAS</li><li>Fasting serum insulin</li><li>Fasting serum glucose*</li><li>hs-CRP*</li><li>Insulin sensitivity index</li></ul><p>*not prespecified in protocol<br/> </p><p><b>Other outcome(s):</b> none</p>,"<p><b>Country: </b>Poland</p><p><b>Setting: </b>Division of Fertility and Reproductive Endocrinology, Poznan University of Medical Sciences</p><p><b>Funding: </b>Polish State Committee for Scientific Research grant and Eunice Kennedy Shriver National Institute of Child Health and Human Development grant; Study drugs were supplied by pharmaceutical companies (i.e. simvastatin from Polfa Grodzisk Mazowiecki and OCP from Organone Polska).</p><p><b>Trial registration:</b> <a href=""https://clinicaltrials.gov/ct2/show/NCT00396513"" type=""EXTERNAL"">clinicaltrials.gov/ct2/show/NCT00396513</a></p>"
Duleba 2006,2006,PUB,2836468,NCT00365638,<p><b>Sequence generation and allocation: </b>block randomisation (blocks of 10) with sealed envelopes</p><p><b>Blinding:</b> open-label</p><p><b>Study period:</b> April–August 2004</p>,"<p><b>Inclusion criteria</b></p><ul><li>PCOS diagnosis according to Rotterdam European Society for Human Reproduction and Embryology (ESHRE)/American Society for Reproduction Medicine (ASRM)-sponsored PCOS Consensus Workshop criteria for PCOS</li><li>No planned pregnancy during the study period</li></ul><p><b>Exclusion criteria</b></p><ul><li>Congenital adrenal hyperplasia, endocrinopathies, androgen secreting tumours, thyroid disease, hyperprolactinaemia, diabetes mellitus</li><li>Use of any OCP or other steroids or medications that interfere with steroid hormones, ovarian functions, insulin sensitivity, or lipid metabolism within 3 months prior to start of</li><li>Contraindications to OCP</li></ul><p><b>Compliance to statins:</b> not reported</p>",<p><b>Intervention(s)</b></p><ul><li>Simvastatin 20mg orally once a day plus OCP containing 20 µg ethinyl oestradiol<sub> </sub>and 150 µg desogestrel</li></ul><p><b>Comparator(s)</b></p><ul><li>OCP (20 µg ethinyl oestradiol<sub> </sub>and 150 µg desogestrel) alone</li></ul><p><b>Treatment duration: </b>3 months</p><p><b>Comedication: </b>none</p>,"<p><b>Primary outcome(s)</b></p><ul><li>Serum total testosterone level, measured by chemiluminescence method</li></ul><p><b>Secondary outcome(s)</b></p><ul><li>BMI</li><li>DHEAS</li><li>SHBG</li><li>FSH</li><li>LH</li><li>LH/FSH ratio</li><li>LDL cholesterol</li><li>HDL cholesterol</li><li>Total cholesterol</li><li>Triglycerides</li><li>Fasting insulin</li><li>Insulin AUC</li><li>Fasting glucose</li><li>Glucose AUC</li><li>Quantitative insulin sensitivity check index</li><li>HOMA insulin sensitivity index</li></ul><p><b>Other outcome(s)</b></p><ul><li>Hirsutism measured on the Ferriman-Gallwey scale</li></ul>","<p><b>Country:</b> Poland</p><p><b>Setting:</b> Division of Fertility and Reproductive Endocrinology, Poznan University of Medical Sciences</p><p><b>Funding:</b> drugs supplied by pharmaceutical companies (i.e. simvastatin from Polfa Grodzisk Mazowiecki and OCP from Organone Polska). Supported by NIH grant.</p><p><b>Trial registration:</b> no</p>"
Mehrabian 2016,2016,PUB,22489053,,<p><b>Sequence generation and allocation: </b>participants allocated to 3 groups randomly in 1:1:1 allocation ratio; allocation was concealed using sealed envelopes.</p><p><b>Blinding:</b> single-blind (physician)</p><p><b>Study period:</b> April 2013–November 2014</p>,"<p><b>Inclusion criteria</b></p><ul><li>PCOS diagnosis according to Rotterdam diagnostic criteria: ≥ 2 of:</li><ul><li>ovulatory dysfunction as oligo-ovulation or anovulation;</li><li>biochemical or clinical evidence of hyperandrogenism; or</li><li>polycystic ovaries as viewed by transvaginal ultrasound.</li></ul><li>Age ≥ 18 years</li><li>Single</li><li>No evidence of thyroid dysfunction, Cushing's syndrome, or hyperprolactinemia</li><li>Normal kidney function, bilirubin level, and serum aminotransferases</li></ul><p><b>Exclusion criteria</b></p><ul><li>Non-compliance with study protocol or unwillingness to continue study</li><li>Emerging side effects of drugs or contraindication</li><li>Smoking</li><li>Breast cancer</li><li>Use of drug that probably affects ovarian function, insulin sensitivity, or lipid profile</li><li>Contraindication to study drugs</li></ul><p><b>Compliance to statins:</b> not reported</p>",<p><b>Intervention(s)</b></p><ul><li>Simvastatin 20 mg daily</li></ul><p><b>Comparator(s)</b></p><ul><li>Flutamide 62.5 mg daily plus low-dose OCP (levonorgestrel 0.15 mg plus ethinyl oestradiol<sub> </sub>0.03 mg<sub> </sub>daily)</li><li>Metformin 1000 mg daily</li></ul><p><b>Treatment duration</b>: 6 months</p><p><b>Comedication: </b>none</p>,"<p><b>Primary outcome(s)</b></p><ul><li>Insulin resistance, defined as HOMA-IR ≥ 2.5 (HOMA-IR = fasting serum insulin (micro U/mL) × fasting plasma glucose (mg/dL)/22.5)</li><li>Fasting blood sugar</li><li>CRP</li><li>Blood pressure</li></ul><p><b>Secondary outcome(s)</b></p><ul><li>BMI</li><li>Waist circumference</li></ul><p><b>Other outcome(s)</b></p><ul><li>HDL cholesterol*</li><li>Triglycerides*</li></ul><p>*not prespecified in protocol</p>","<p><b>Country:</b> Iran</p><p><b>Setting: </b>midwifery clinic of Al-Zahra Hospital and Beheshti Hospital, Isfahan, Iran</p><p><b>Funding: </b>Isfahan University of Medical Sciences funded this study.</p><p><b>Trial registration: </b><a href=""https://fa.irct.ir/trial/7999"" type=""EXTERNAL"">fa.irct.ir/trial/7999</a></p>"
Puurunen 2013,2009,PUB,2836477,NCT01072097,<p><b>Sequence generation and allocation: </b>Computer-generated randomisation list with blocks of 6. Sequence generation and allocation of treatment was performed by a person not involve in the study directly; sealed sequentially numbered packages of study medications were prepared.</p><p><b>Blinding:</b> double-blind</p><p><b>Study period:</b> September 2007–January 2011</p>,"<p><b>Inclusion criteria</b></p><ul><li>PCOS diagnosis according to Rotterdam criteria 2003: ≥ 2 of:</li><ul><li>oligomenorrhea;</li><li>hyperandrogenism; or </li><li>polycystic ovaries on ultrasound.</li></ul><li>Age 29–50 years</li><li>Not menopausal</li><li>Safe non-hormonal contraception</li></ul><p><b>Exclusion criteria</b></p><ul><li>Type 2 diabetes mellitus</li><li>Use of medication affecting glucose tolerance, lipid metabolism, or steroid synthesis in the preceding 3 months</li><li>Menopause</li><li>Regular smoking</li><li>Abuse of alcohol</li><li>History of ovarian drilling, oophorectomy, or hysterectomy</li><li>Contraindication for the use of atorvastatin</li></ul><p><b>Compliance to statins:</b> not reported</p>",<p><b>Intervention(s)</b></p><ul><li>Atorvastatin 20 mg once daily (every evening)</li></ul><p><b>Comparator(s)</b></p><ul><li>Placebo</li></ul><p><b>Treatment duration: </b>6 months (with follow-up at 3 months)</p><p><b>Comedication:</b> none</p>,"<p><b> Primary outcome(s)</b></p><ul><li>Androgen secretion (total testosterone, DHEAS, SHBG)</li><li>Glucose metabolism (fasting glucose, insulin, insulin sensitivity)</li></ul><p><b>Secondary outcomes</b></p><ul><li>hs-CRP</li><li>Total cholesterol</li><li>HDL cholesterol</li><li>LDL cholesterol</li><li>Triglycerides</li><li>FSH </li><li>LH</li><li>WHR</li><li>BMI</li><li>Systolic blood pressure</li><li>Diastolic blood pressure</li><li>Creatinine</li><li>ALAT</li></ul><p><b>Other outcome(s):</b> none</p>","<p><b>Country:</b> Finland</p><p><b>Setting: </b>Oulu University Hospital, Oulu, Finland</p><p><b>Funding: </b>Academy of Finland, the Sigrid Jusélius Foundation, the Finnish Medical Foundation, the National Clinical Graduate School, the Research Foundation of Obstetrics and Gynecology, Oulu University Scholarship Foundation, the North Ostrobothnia Regional fund of the Finnish Cultural Foundation, the Tyyni Tani Foundation of the University of Oulu, and the Finnish-Norwegian Medical Foundation. Atorvastatin and placebo were provided by Pfizer Inc.</p><p><b>Trial registration:</b> <a href=""https://clinicaltrials.gov/ct2/show/NCT01072097"" type=""EXTERNAL"">clinicaltrials.gov/ct2/show/NCT01072097</a>; <a href=""https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003584-31"" type=""EXTERNAL"">www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003584-31</a></p>"
Raja-Khan 2011,2009,PUB,2836480,NCT00529542,<p><b>Sequence generation and allocation: </b>biostatistician generated a permuted block randomisation scheme for the allocation sequence. A different person (pharmacist) did over-encapsulation of the atorvastatin and placebo.</p><p><b>Blinding:</b> double-blind</p><p><b>Study period: </b>20 October 2006 – 8 September 2008</p>,"<p><b>Inclusion criteria</b></p><ul><li>PCOS (1990 NIH criteria)</li><li>LDL cholesterol &gt; 100 mg/dL (cut-off according to NCEP guideline)</li></ul><p><b>Exclusion criteria</b></p><ul><li>Current pregnancy or breastfeeding</li><li>Current use of oral contraceptives or progestins</li><li>Insulin-sensitising medications</li><li>Thyroid disease, hyperprolinaemia, active liver disease, type 1 or type 2 diabetes</li></ul><p><b>Compliance to statins: </b>not reported</p>","<p><b>Intervention(s)</b></p><ul><li>Atorvastatin 60 mg/day, orally</li></ul><p><b>Comparator(s)</b></p><ul><li>Placebo</li></ul><p><b>Treatment duration:</b> 1.5 month (6 weeks)</p><p><b>Comedication</b></p><ul><li>Oral contraceptives (1 woman)</li><li>Antihypertensives (2 women)</li></ul>","<p><b>Primary outcome(s)</b></p><ul><li>Improvement of vascular function: brachial artery flow-mediated dilation (FMD), peak brachial artery conductance, </li><li>hs-CRP</li><li>Androgen levels: total testosterone, free testosterone, androstenedione, DHEAS</li></ul><p><b>Secondary outcome(s)</b></p><ul><li>BMI</li><li>Systolic blood pressure</li><li>Diastolic blood pressure</li><li>Total cholesterol</li><li>HDL cholesterol</li><li>LDL cholesterol</li><li>Triglycerides</li><li>AUC insulin</li><li>Mean ovarian volume</li></ul><p><b>Other outcome(s):</b> none</p>","<p><b>Country: </b>USA</p><p><b>Setting:</b> not reported</p><p><b>Funding:</b> NIH grant number K12HD055882, &quot;Career Development Program in Women's Health Research at Penn State,&quot; from the National Institute of Child Health and Human Development (NICHD), GCRC grant M01 RR10732 and construction grant C06 RR016499 to Pennsylvania State University, and a research grant from Pfizer.</p><p><b>Trial registration: </b><a href=""https://www.clinicaltrials.gov/ct2/show/NCT00529542"" type=""EXTERNAL"">www.clinicaltrials.gov/ct2/show/NCT00529542</a></p><p>The trial was terminated early because of lack of funding for the required sample size.</p>"
Sathyapalan 2009,2009,MIX,2836485,,<p><b>Sequence generation and allocation:</b> computer-generated randomisation list. Personnel not involved in the trial were responsible for labelling.</p><p><b>Blinding:</b> double-blind</p><p><b>Study period: </b>13 July 2006–1 May 2008</p>,"<p><b>Inclusion criteria</b></p><ul><li>PCOS based on Rotterdam criteria (all 3):</li><ul><li>clinical and biochemical evidence of hyperandrogenaemia (Ferriman-Gallwey score &gt; 8; free androgen index);</li><li>oligomenorrhea or amenorrhoea; and</li><li>polycystic ovaries in transvaginal ultrasound.</li></ul><li>Age 18–40 years</li><li>No concurrent illness</li><li>No medicine, OTC, or oral contraceptive products in preceding 6 months that may affect insulin sensitivity, lipid profile, or ovarian function</li><li>No previous statin therapy</li><li>Use of barrier method of contraception</li></ul><p><b>Exclusion criteria</b></p><ul><li>Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, Cushing's disease, or androgen-secreting tumour</li><li>No concurrent illness</li><li>Unwillingness to allow disclosure to their GPs</li><li>No barrier or oral progesterone contraception</li></ul><p><b>Compliance to statins:</b> 99%</p>",<p><b>Intervention(s)</b></p><ul><li>Atorvastatin 20 mg daily. Participants were advised not to alter their usual dietary and exercise habits.</li></ul><p><b>Comparator(s)</b></p><ul><li>Placebo. Participants were advised not to alter their usual dietary and exercise habits.</li></ul><p><b>Treatment duration:</b> 3 months</p><p><b>Comedication: </b>none</p>,<p><b>Primary outcome(s)</b></p><ul><li>hs-CRP </li></ul><p><b>Secondary outcome(s)</b></p><ul><li>HOMA-IR</li><li>Total testosterone</li><li>Weight</li><li>BMI</li><li>Waist</li><li>Glucose</li><li>Free androgen index</li><li>SHBG</li><li>Total cholesterol</li><li>HDL cholesterol</li><li>LDL cholesterol</li><li>Triglycerides</li><li>Lipid levels</li><li>Insulin levels</li></ul>,"<p><b>Country: </b>UK</p><p><b>Setting:</b> not stated clearly. Presumed to be Hull and East Yorkshire's Women's and Children's hospital, UK from the address of the study authors and name of the local ethical committee mentioned in the study.</p><p><b>Funding:</b> unrestricted grant from Pfizer</p><p><b>Trial registration:</b> <a href=""https://www.isrctn.com/ISRCTN24474824"" type=""EXTERNAL"">www.isrctn.com/ISRCTN24474824</a> (retrospectively registered)</p>"
